



S100A4 inhibitor “Minnetamide” for prostate cancer treatment

Technology No. 2020-242

IP Status: Provisional Patent Application Filed; **Application #:** 63/037,355

Application

- Prostate cancer treatment

Technology Overview

Current treatments for prostate cancers (PC) are highly variable in their efficacy, particularly in the case of aggressive forms of cancers such as neuroendocrine type PC (NEPC). The technology is a small molecule (called “S100A-Minnetamide”) that inhibits a novel drug target, S100 calcium-binding protein A4 (S100A4). In animal models of disease, S100A-Minnetamide is well tolerated, bioavailable and results in reduced cancer growth

Phase of Development

In vitro and in vivo/animal studies completed.

Researchers

Mohammad Saleem Bhat, PhD
Associate Professor, Dept. of Urology
[External Link](http://www.cancer.umn.edu) (www.cancer.umn.edu)

Publications

- [“S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9.”](#) PNAS, 2006.
- [“The S100A4 Oncoprotein Promotes Prostate Tumorigenesis in a Transgenic Mouse Model: Regulating NFκB through the RAGE Receptor.”](#) Genes and Cancer, 2013.

Desired Partnerships

This technology is now available for:

- License
- Sponsored research
- Co-development

Please contact us to share your business' needs and learn more.

<https://license.umn.edu/product/s100a4-inhibitor-minnetamide-for-prostate-cancer-treatment>